Coronaries Screenshot LP

Why CT plaque quantification?

Traditional stenosis assessment doesn’t tell the whole story.


CT-derived plaque quantification provides a comprehensive, objective, and actionable assessment of coronary atherosclerosis by quantifying total, non-calcified, and high-risk plaque¹. This insight enhances diagnosis, improves risk stratification, and informs more personalized care.

  • Proven Predictive Value:
    • Offers superior prognostic information compared to stenosis-based or traditional risk-factor assessments8
    • Identifies High-Risk features such as low-attenuation plaques (<60HU) and remodeling index whichin dependently predict adverse cardiac events2,3,4
  • Reliable and Reproducible:
    • Demonstrates strong concordance with invasive imaging (IVUS), in assessing plaque volume and composition5
    • AI-enhanced volumetric analysis ensures fast, consistent, and reproducible results.
  • Personalized Treatment & Longitudinal Monitoring:
    • Enables tracking of treatment-induced changes, such as statin-induced plaque regression6,7
    • Detects vulnerable plaque features (e.g., low-attenuation <30 HU, positive remodeling) linked to elevated event risk10
    • Engage patients with visual evidence: Support patient adherence with intuitive, visual explanations of disease progression
  • Better Cardiovascular Outcomes Through Prevention:
    • CCTA offers incremental predictive value beyond coronary calcification and clinical scores, by assessing non-calcified and low-attenuation plaque burden9.
    • CCTA has been shown to modestly encourage healthier lifestyle choices, greater acceptance of preventive treatments, and positive changes in risk factors11.

Why Choose cvi42 | Plaque*?

Fast. Reproducible. Integrated.

cvi42 | Plaque empowers cardiac imaging teams with AI-enabled, on-premise quantification of atherosclerotic burden. It delivers precise measurements of plaque volume, burden, composition, and distribution, all fully integrated into your CT workflow.

No external processing. No extra imaging.

AI-Enabled Automation:

  • Automated coronary lumen and wall segmentation ensures rapid, reproducible plaque quantification
  • Per-lesion and per-vessel analysis provides detailed assessment of calcified, non-calcified, and low attenuation plaque for precise risk stratification
  • Remodeling index calculation identifies high-risk plaques beyond stenosis severity
Plaque measurements 6.3
Coronaries Screenshot LP

Full User Control:

  • Manual controls allow adjustment of lumen, vessel wall, and lesion annotations as needed
  • Lesion-level occlusion marking enhances detection of chronic total occlusions and supports revascularization planning
  • Option of single- or dual-reference markers allows flexibility in grading stenosis

 

Smart, Actionable Reporting

  • Generate vessel-level and total plaque summaries for fast and
    clear interpretation
  • Visual, patient-friendly outputs improve communication and support shared decision-making
  • Integrated CAD-RADS classification supports standardized reporting and facilitates communication across the care team
CVIReport00002_Page_3
CVIReport00002_Page_2-1
Coronary Plaque screenshot-1

Ready to bring cvi42 | Plaque to your practice?

Contact Us

References

1. Mézquita AJV, Biavati F, Falk V, et al. Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group. Nat Rev Cardiol. 2023;20(10):696-714. doi:10.1038/s41569-023-00880-4
2. Feuchtner G, Kerber J, Burghard P, et al. The high-risk criteria low-attenuation plaque <60 HU and the napkinring sign are the most powerful predictors of MACE: a long-term follow-up study. Eur Heart J Cardiovasc Imaging. 2017;18(7):772-779. doi:10.1093/ehjci/jew167
3. Deseive S, Straub R, Kupke M, et al. Quantification of coronary low-attenuation plaque volume for long-term prediction of cardiac events and reclassification of patients. J Cardiovasc Comput Tomogr. 2018;12(2):118-124. doi:10.1016/j.jcct.2018.01.002
4. Williams MC, Moss AJ, Dweck M, et al. Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOTHEART Study. J Am Coll Cardiol. 2019;73(3):291-301. doi:10.1016/j.jacc.2018.10.066
5. Shaw LJ, Blankstein R, Bax JJ, et al. Society of Cardiovascular Computed Tomography / North American Society of Cardiovascular Imaging - Expert Consensus Document on Coronary CT Imaging of Atherosclerotic Plaque. J Cardiovasc Comput Tomogr. 2021;15(2):93-109. doi:10.1016/j.jcct.2020.11.002
6. Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression - a serial coronary CT angiography study. Atherosclerosis. 2013;231(2):198-204. doi:10.1016/j.atherosclerosis.2013.08.019
7. Lee SE, Chang HJ, Sung JM, et al. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. JACC Cardiovasc Imaging. 2018;11(10):1475-1484. doi:10.1016/j.jcmg.2018.04.015
8. Hadamitzky M, Achenbach S, Al-Mallah M, et al. Optimized prognostic score for coronary computed tomographic angiography: results from the CONFIRM registry (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry). J Am Coll Cardiol. 2013;62(5):468-476. doi:10.1016/j.jacc.2013.04.064
9. Williams MC, Kwiecinski J, Doris M, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720
10. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54(1):49-57. doi:10.1016/j.jacc.2009.02.068

*cvi42 | Plaque is not available for clinical use in the USA.

Brief Summary: Indications, contraindications warnings and precautions can be found in the product labelling.
Disclaimer: Not all modules or features are available in every region. Contact your local Circle representative for all regional availability.
CAUTION: Federal law (USA) restricts these devices for sale by, or on the order of a physician. The system is intended for use only by trained Healthcare Professionals.